Active Breast Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Breast Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Breast Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Breast Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Breast Cancer Clinical Trial FAQ

Are there breast cancer clinical trials for triple-negative breast cancer (TNBC)?

Yes — TNBC is one of the most active areas of clinical research in oncology. Trials are currently testing checkpoint inhibitors (like pembrolizumab), antibody-drug conjugates (like sacituzumab govitecan), PARP inhibitors for BRCA-mutated TNBC, and novel immunotherapy combinations. TNBC trials are available for both early-stage (neoadjuvant/adjuvant) and metastatic disease.

Can early-stage breast cancer patients join clinical trials, or only metastatic patients?

Both. There are separate trials for early-stage breast cancer (often testing treatments before surgery, called neoadjuvant, or after surgery, called adjuvant) and for metastatic or advanced breast cancer. Early-stage trials often have stricter eligibility around tumor size, lymph node status, and whether the patient has received prior therapy.

Do I need BRCA genetic testing before joining a breast cancer trial?

Not for all trials, but many HER2-negative and triple-negative breast cancer trials now require or prefer BRCA1/2 testing because PARP inhibitors (olaparib, talazoparib) are FDA-approved specifically for BRCA-mutated breast cancer. If you haven't had genetic testing, ask your oncologist — it can open doors to additional trial options.

Can I participate in a breast cancer trial while still receiving standard treatment?

Some trials add an investigational drug on top of standard chemotherapy or hormone therapy. Others require stopping prior therapy before enrolling. The trial protocol will specify what is allowed and what is not. Trialify's eligibility questionnaire highlights these requirements in plain language so you know what to discuss with your doctor.

What should I bring to my appointment when discussing a breast cancer trial?

Bring the NCT number, your receptor status (ER/PR/HER2), staging information, and a list of all prior treatments. Trialify's doctor summary consolidates this into a one-page printout that includes the trial name, your match assessment, and key eligibility questions — so your oncologist can evaluate it quickly.

Explore Other Cancer Trial Guides

• Triple-Negative Breast Cancer (TNBC) — Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and HER2 expression, making it harder to treat with hormone or HER2-targeted therapy. Immunotherapy (pembrolizumab), antibody-drug conjugates (sacituzumab govitecan), and PARP inhibitors for BRCA-mutated TNBC are among the most active trial areas.
• HER2-Positive Breast Cancer — HER2-positive breast cancer overexpresses the HER2 protein, making it responsive to targeted therapies. Trials are advancing trastuzumab deruxtecan (T-DXd), tucatinib combinations, and novel HER2-targeted approaches — including emerging options for HER2-low disease.
• Ovarian Cancer — Ovarian cancer trials are investigating PARP inhibitor combinations, antibody-drug conjugates, folate receptor-targeted therapy, and immunotherapy — with studies available for both platinum-sensitive and resistant disease.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.